Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis

A method for enhancing hemostasis by administering to the individual effective doses of Recombinant human Erythropoietin so that the bleeding is stopped or significantly reduced.

A method for treating an individual patient bleeding from an organ or body part having benign or malignant lesions, comprising

• administering to the individual effective doses of Recombinant human Erythropoietin so that the bleeding is stopped or significantly reduced, wherein the organ or body part, has surgical, traumatic or difficult to heal lesions.

A method for treating an individual patient bleeding from an organ or body part having benign or malignant lesions, comprising

• administering to the individual effective doses of Recombinant human Erythropoietin so that the bleeding is stopped or significantly reduced, wherein the individual has radiation injury.

A method for treating an individual patient bleeding from an organ or body part having benign or malignant lesions, comprising

• administering to the individual effective doses of Recombinant human Erythropoietin so that the bleeding is stopped or significantly reduced, wherein the individual is bleeding from an organ transplant or skin graft.

A method for treating an individual patient bleeding from an organ or body part having benign or malignant lesions, comprising

• administering to the individual effective doses of Recombinant human Erythropoietin so that the bleeding is stopped or significantly reduced, where patients are HIV positive.

A method for treating an individual patient bleeding from an organ or body part having benign or malignant lesions, comprising

• administering to the individual effective doses of Recombinant human Erythropoietin so that the bleeding is stopped or significantly reduced, in which human Recombinant human Erythropoietin is administered during an initial treatment in dosages between 15,000 to 140,000 units per week until the bleeding stops, and is then continued to be administered on a reduced basis thereafter.

A method for treating bleeding in patients with lesions that bleed excessively in patients with hemostatic or coagulation abnormalities, or patients on anticoagulants/antiplatelet drugs for other coexistent conditions, comprising the concomitant administration of effective doses of Recombinant human Erythropoietin with the anticoagulant/antiplatelet drug.

The method of administering Recombinant human Erythropoietin prophylactically or therapeutically to patients with anemia who cannot be transfused and who need surgery comprising administering an effective amount of Recombinant human Erythropoietin during and after surgery in order to minimize the blood loss.

The method of administering Recombinant human Erythropoietin to patients undergoing surgical procedures which require infusion/perfusion with an anticoagulant simultaneously with the surgical procedure, increasing the risk of bleeding, comprising administering an effective dose of Recombinant human Erythropoietin before, during and after the surgical procedure in order to limit the blood loss.

The method of treating bleeding from the gastrointestinal mucosa by the administration of Erythropoietin orally, as an enema, or as a suppository or lavaging the bleeding segment of a bowel with a solution containing Erythropoietin, depending on the bleeding segment in order to decrease or stop the bleeding.

A method for treating an individual patient bleeding from an organ or body part having benign or malignant lesions and a low platelet count and low Hemoglobin level, comprising

• increasing the individual's platelet count and Hemoglobin level and stopping or significantly reducing bleeding by administering to the individual effective doses of Recombinant human Erythropoietin by subcutaneous, intravenous or oral administration.